SEC Tracker
Get the app

111 YI

111 FY 2021: revenue $12.4B, up 51%; diluted EPS −$4.04

Form
20-F
Filed
Period
Importance
Notable
Document
20-F

Key figures from this report

These are the numbers 111 reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$12.4B+51% from $8.2B in FY 202020-F income statement, on EDGAR
  2. Diluted EPS−$4.04Against −$2.77 in FY 202020-F income statement, on EDGAR
  3. Cash and cash equivalents$661.4M−44% from $1.2B in FY 2020Cash and equivalents only; the company page adds short-term investments.20-F balance sheet, on EDGAR
  4. Cash from operations−$688.8MAgainst −$116.8M in FY 202020-F cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when 111 files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 5912 and related industry codes: the same peer list as the financial tables.

  1. AiXin Life International AIXN public float $884K, Jun 30, 2025
  2. TREES Corp (Colorado) CANN
  3. CVS Health CVS public float $86.4B, Jun 30, 2025
  4. Flowerkist Skin Care & Cosmetics FKST
  5. Guardian Pharmacy Services GRDN public float $412M, Jun 30, 2025